Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Nanoparticle-detained toxins for safe and effective vaccination



Toxoid vaccines—vaccines based on inactivated bacterial toxins—are routinely used to promote antitoxin immunity for the treatment and prevention of bacterial infections1,2,3,4. Following chemical or heat denaturation, inactivated toxins can be administered to mount toxin-specific immune responses. However, retaining faithful antigenic presentation while removing toxin virulence remains a major challenge and presents a trade-off between efficacy and safety in toxoid development. Here, we show a nanoparticle-based toxin-detainment strategy that safely delivers non-disrupted pore-forming toxins for immune processing. Using erythrocyte membrane-coated nanoparticles and staphylococcal α-haemolysin, we demonstrate effective virulence neutralization via spontaneous particle entrapment. Compared with vaccination with heat-denatured toxin, mice vaccinated with the nanoparticle-detained toxin showed superior protective immunity against toxin-mediated adverse effects. We find that the non-disruptive detoxification approach benefited the immunogenicity and efficacy of toxoid vaccines. We anticipate that this study will open new possibilities in the preparation of antitoxin vaccines against the many virulence factors that threaten public health.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic and in vitro characterizations.
Figure 2: Nanotoxoid(Hla) neutralizes Hla virulence.
Figure 3: Nanotoxoid(Hla) vaccinations elicit strong Hla-specific antibody responses.
Figure 4: Nanotoxoid(Hla) vaccinations bestow strong protective immunity.

Similar content being viewed by others


  1. Kitchin, N. R. Review of diphtheria, tetanus and pertussis vaccines in clinical development. Exp. Rev. Vaccines 10, 605–615 (2011).

    Article  CAS  Google Scholar 

  2. Greenberg, R. N., Marbury, T. C., Foglia, G. & Warny, M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30, 2245–2249 (2012).

    Article  CAS  Google Scholar 

  3. Mortimer, E. A. Jr. Immunization against infectious disease. Science 200, 902–907 (1978).

    Article  Google Scholar 

  4. Holmgren, J. et al. Development of improved cholera vaccine based on subunit toxoid. Nature 269, 602–604 (1977).

    Article  CAS  Google Scholar 

  5. Gentschev, I., Dietrich, G. & Goebel, W. The E. coli alpha-hemolysin secretion system and its use in vaccine development. Trends Microbiol. 10, 39–45 (2002).

    Article  CAS  Google Scholar 

  6. Cover, T. L. & Blanke, S. R. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nature Rev. Microbiol. 3, 320–332 (2005).

    Article  CAS  Google Scholar 

  7. Bubeck Wardenburg, J. & Schneewind, O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205, 287–294 (2008).

    Article  Google Scholar 

  8. Parish, H. J. & Cannon, D. A. Staphylococcal infection: antitoxic immunity. Br. Med. J. 1, 743–747 (1960).

    Article  CAS  Google Scholar 

  9. Metz, B. et al. Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J. Biol. Chem. 279, 6235–6243 (2004).

    Article  CAS  Google Scholar 

  10. Cryz, S. J. Jr, Furer, E. & Germanier, R. Effect of chemical and heat inactivation on the antigenicity and immunogenicity of Vibrio cholerae. Infect. Immunol. 38, 21–26 (1982).

    Google Scholar 

  11. Vogel, F. R. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 30(Suppl 3), S266–S270 (2000).

    Article  CAS  Google Scholar 

  12. Kennedy, A. D. et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 202, 1050–1058 (2010).

    Article  Google Scholar 

  13. Adhikari, R. P. et al. Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One 7, e38567 (2012).

    Article  CAS  Google Scholar 

  14. Jang, S. I. et al. Vaccination with Clostridium perfringens recombinant proteins in combination with Montanide ISA 71 VG adjuvant increases protection against experimental necrotic enteritis in commercial broiler chickens. Vaccine 30, 5401–5406 (2012).

    Article  CAS  Google Scholar 

  15. Kirkham, L. A. et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect. Immunol. 74, 586–593 (2006).

    Article  CAS  Google Scholar 

  16. Hu, C. M. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980–10985 (2011).

    Article  CAS  Google Scholar 

  17. Hu, C. M., Fang, R., Copp, J., Luk, B. & Zhang, L. A biomimetic nanosponge that absorbs pore-forming toxins. Nature Nanotech. 8, 336–340 (2013).

    Article  CAS  Google Scholar 

  18. Dobrovolskaia, M. A. & McNeil, S. E. Immunological properties of engineered nanomaterials. Nature Nanotech. 2, 469–478 (2007).

    Article  CAS  Google Scholar 

  19. Moon, J. J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nature Mater. 10, 243–251 (2011).

    Article  CAS  Google Scholar 

  20. Sun, C. et al. Circumventing anti-vector immunity using adenovirus-infected blood cells for repeated application of adenovirus vectored vaccines: proof-of-concept in rhesus macaques. J. Virol. 86, 11031–11042 (2012).

    Article  CAS  Google Scholar 

  21. Roberts, D. M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243 (2006).

    Article  CAS  Google Scholar 

  22. Skean, J. D. & Overcast, W. W. Efficacy of staphylococcal vaccines to elicit antistaphylococcal alpha-hemolysin in dairy cows. J. Dairy Sci. 51, 1239–1242 (1968).

    Article  CAS  Google Scholar 

  23. Elamanchili, P., Diwan, M., Cao, M. & Samuel, J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22, 2406–2412 (2004).

    Article  CAS  Google Scholar 

  24. Moon, J. J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl Acad. Sci. USA 109, 1080–1085 (2012).

    Article  CAS  Google Scholar 

  25. Inoshima, I. et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nature Med. 17, 1310–1314 (2011).

    Article  CAS  Google Scholar 

  26. Moon, J. J., Huang, B. & Irvine, D. J. Engineering nano- and microparticles to tune immunity. Adv. Mater. 24, 3724–3746 (2012).

    Article  CAS  Google Scholar 

  27. Swartz, M. A., Hirosue, S. & Hubbell, J. A. Engineering approaches to immunotherapy. Sci. Transl. Med. 4, 148rv149 (2012).

    Article  Google Scholar 

  28. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol. 25, 1159–1164 (2007).

    Article  CAS  Google Scholar 

  29. Hubbell, J. A., Thomas, S. N. & Swartz, M. A. Materials engineering for immunomodulation. Nature 462, 449–460 (2009).

    Article  CAS  Google Scholar 

  30. Parodi, A. et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nature Nanotech. 8, 61–68 (2013).

    Article  CAS  Google Scholar 

Download references


This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (award no. R01DK095168) and by the National Science Foundation (grant DMR-1216461). B.L. is supported by a National Institutes of Health training grant (R25CA153915) from the National Cancer Institute.

Author information

Authors and Affiliations



L.Z. conceived and designed the experiments with C-M.H., R.F. and B.L. Experiments were performed by C-M.H., R.F. and B.L. All authors analysed and discussed the data and wrote the manuscript.

Corresponding author

Correspondence to Liangfang Zhang.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

Supplementary Information (PDF 4796 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hu, CM., Fang, R., Luk, B. et al. Nanoparticle-detained toxins for safe and effective vaccination. Nature Nanotech 8, 933–938 (2013).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing